Clinical Trials · NCT06965413
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
- Phase
- Phase 2
- Recruitment status
- Active Not Recruiting
- Sponsor
- Hoffmann-La Roche
- Enrollment
- 285
- Start date
- May 2025
- Locations
- 35 sites, 4 countries
- Primary endpoint
- Percent Change From Baseline in Body Weight